Kristen Hege

11.7k total citations · 2 hit papers
90 papers, 5.2k citations indexed

About

Kristen Hege is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Kristen Hege has authored 90 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 42 papers in Immunology and 33 papers in Molecular Biology. Recurrent topics in Kristen Hege's work include CAR-T cell therapy research (41 papers), Immunotherapy and Immune Responses (25 papers) and Multiple Myeloma Research and Treatments (16 papers). Kristen Hege is often cited by papers focused on CAR-T cell therapy research (41 papers), Immunotherapy and Immune Responses (25 papers) and Multiple Myeloma Research and Treatments (16 papers). Kristen Hege collaborates with scholars based in United States, France and Spain. Kristen Hege's co-authors include Carl H. June, John Nemunaitis, Steven G. Deeks, Ronald T. Mitsuyasu, Andy Lin, David T. Scadden, Peter A. Anton, Natalie Sacks, Karin Jooss and Margo R. Roberts and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Kristen Hege

89 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

2012 502 citations Kristen Hege et al. profile →
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

2021 236 citations Mehmet Samur, Mariateresa Fulciniti et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kristen Hege United States	36	3.6k	2.5k	1.9k	887	792	90	5.2k
Hans J. Stauss United Kingdom	42	2.9k 0.8×	3.6k 1.5×	1.5k 0.8×	1.2k 1.3×	480 0.6×	136	5.6k
Mikhail Roshal United States	27	2.3k 0.6×	862 0.3×	1.4k 0.7×	593 0.7×	1.2k 1.5×	103	4.3k
Carmine Carpenito United States	22	4.3k 1.2×	2.8k 1.1×	1.6k 0.8×	1.4k 1.6×	168 0.2×	37	5.8k
Mojgan Ahmadzadeh United States	23	3.4k 0.9×	4.7k 1.9×	984 0.5×	478 0.5×	336 0.4×	30	5.9k
Joseph A. Fraietta United States	25	3.6k 1.0×	2.0k 0.8×	1.7k 0.9×	924 1.0×	204 0.3×	80	4.9k
Kathleen E. Morton United States	17	6.0k 1.7×	6.2k 2.5×	1.9k 1.0×	1.4k 1.6×	219 0.3×	19	8.8k
Sharon Mavroukakis United States	21	7.6k 2.1×	7.0k 2.8×	2.3k 1.2×	1.9k 2.1×	270 0.3×	36	10.5k
Linda Rogers-Freezer United States	9	4.9k 1.4×	4.4k 1.8×	1.6k 0.8×	1.4k 1.6×	205 0.3×	10	6.4k
Zhaohui Zheng United States	17	5.6k 1.5×	2.1k 0.8×	1.8k 0.9×	1.7k 1.9×	622 0.8×	32	6.5k
Marianna Sabatino United States	28	3.5k 1.0×	1.7k 0.7×	1.4k 0.7×	970 1.1×	433 0.5×	87	4.8k

Countries citing papers authored by Kristen Hege

Since Specialization

Citations

This map shows the geographic impact of Kristen Hege's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristen Hege with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristen Hege more than expected).

Fields of papers citing papers by Kristen Hege

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristen Hege. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristen Hege. The network helps show where Kristen Hege may publish in the future.

Co-authorship network of co-authors of Kristen Hege

This figure shows the co-authorship network connecting the top 25 collaborators of Kristen Hege. A scholar is included among the top collaborators of Kristen Hege based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristen Hege. Kristen Hege is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Connarn, Jamie N., Han Witjes, Rik de Greef, et al.. (2023). Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1687–1697. 6 indexed citations

Strati, Paolo, Eliza A. Hawkes, Nilanjan Ghosh, et al.. (2021). Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood. 138(Supplement 1). 2493–2493. 15 indexed citations

Braverman, Julia, et al.. (2021). PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial. Value in Health. 24. S61–S61. 1 indexed citations

Samur, Mehmet, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, et al.. (2020). Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma. Blood. 136(Supplement 1). 14–14. 10 indexed citations

Münster, Pamela N., Monica Mita, Amit Mahipal, et al.. (2019). First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. SHILAP Revista de lepidopterología. 1 indexed citations

Costa, Luciano J., Sandy W. Wong, Arancha Bermúdez, et al.. (2019). First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Blood. 134(Supplement_1). 143–143. 132 indexed citations

Uy, Geoffrey L., Mark D. Minden, Pau Montesinos, et al.. (2019). Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. Blood. 134(Supplement_1). 232–232. 23 indexed citations

Rasco, Drew, Kyriakos P. Papadopoulos, Michael Pourdehnad, et al.. (2018). A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clinical Cancer Research. 25(1). 90–98. 74 indexed citations

Shah, Nina, Melissa Alsina, David S. Siegel, et al.. (2018). Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. Blood. 132(Supplement 1). 488–488. 66 indexed citations

10.

Michot, Jean‐Marie, Réda Bouabdallah, Jeanette K. Doorduijn, et al.. (2017). CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL). Blood. 130. 411–411. 3 indexed citations

11.

Berdeja, Jesús G., Yi Lin, Noopur Raje, et al.. (2017). Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. Blood. 130(Suppl_1). 740–740. 58 indexed citations

12.

Thijssen, Rachel, Jennifer R. Brown, Stacey M. Fernandes, et al.. (2016). Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 128(4). 574–583. 59 indexed citations

13.

Michot, Jean‐Marie, Jeanette K. Doorduijn, Réda Bouabdallah, et al.. (2016). A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma. Blood. 128(22). 4199–4199. 1 indexed citations

14.

Abadie, Kathleen & Kristen Hege. (2014). Severe refractory autoimmune hemolytic anemia with five-year complete hematologic response to third course of treatment with rituximab: a case report. Journal of Medical Case Reports. 8(1). 175–175. 1 indexed citations

15.

Shih, Kent C., Johanna C. Bendell, Suzanne F. Jones, et al.. (2012). Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.. Journal of Clinical Oncology. 30(15_suppl). 3006–3006. 14 indexed citations

16.

Smith, B. Douglas, Yvette L. Kasamon, Jeanne Kowalski, et al.. (2010). K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. Clinical Cancer Research. 16(1). 338–347. 77 indexed citations

17.

Laheru, Dan, Eric R. Lutz, James M. Burke, et al.. (2008). Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research. 14(5). 1455–1463. 259 indexed citations

18.

Davies, Angela M., Raja Mudad, James Moon, et al.. (2007). PD3-1-7: Phase II trial of autologous cancer vaccine, CG8123 (GVAX), in patients with advanced bronchioloalveolar carcinoma (BAC): a Southwest Oncology Group Study (S0310).. Journal of Thoracic Oncology. 2(8). S461–S461. 5 indexed citations

19.

Kasamon, Yvette L., Carole B. Miller, Christina Y. Chia, et al.. (2006). K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM). Journal of Clinical Oncology. 24(18_suppl). 6509–6509. 10 indexed citations

20.

Hege, Kristen, Karin Jooss, & Drew M. Pardoll. (2006). GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men. International Reviews of Immunology. 25(5-6). 321–352. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact